Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in FGFR-altered Colorectal Cancer
NCT04096417Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Aug 2020
- Primary completion
- May 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in colorectal cancer (CRC), sponsored by Academic and Community Cancer Research United. Started Aug 2020; status: active, not recruiting.
02
Drugs
pemigatinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04096417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096417.